Asahi Kasei has started a Phase I clinical trial in Japan for AK1940, a peptide-based investigational compound for autoimmune diseases. The study will assess pharmacokinetics, safety and tolerability in healthy volunteers.
An experimental ovarian cancer drug, elenagen, more than doubled median survival in a 30-patient mid-stage trial in Belarus. The drug was added to gemcitabine and reduced mortality risk by nearly 60%.
A human study found that epoxy-oxylipins help regulate inflammation and that GSK2256294 increased these molecules, reduced pain faster and lowered intermediate monocytes. The findings map epoxy-oxylipin activity in humans during inflammation.
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly outside of ESKD-related cardiovascular risk. CSL receives $100 million upfront and retains rights to the ESKD indication.
HCW Biologics and WY Biotech closed first-round financing for joint venture Trimmune, granting exclusive worldwide license to develop preclinical TRBC molecule HCW11-006 for $7 million in upfront consideration, with Phase 1 trial planned in China for first half of 2027.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07247734 |
The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation |
RECRUITING | PHASE2 |
| NCT07241741 |
The Predictive Role of Preoperative Pentraxin-3 (PTX3) in Metabolic and Inflammatory Outcomes After Roux-en-Y Gastric Bypass |
COMPLETED | |
| NCT06935838 |
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV |
RECRUITING | PHASE2 |
| NCT06622304 |
Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels |
COMPLETED | |
| NCT06604611 |
Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation |
NOT_YET_RECRUITING | PHASE4 |
| NCT06522750 |
Periodic Fasting for Treatment of Long Covid in Adults: a Pilot Study |
RECRUITING | NA |
| NCT06444763 |
Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population |
COMPLETED | PHASE3 |
| NCT06401785 |
To Evaluate the Efficacy of Oral Molecular Hydrogen Supplement in Patients With Chronic Diseases |
RECRUITING | PHASE2 |
| NCT06363253 |
Pilot Study of the Human Metagenome in Metabolic Diseases |
RECRUITING | |
| NCT05949281 |
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes |
ACTIVE_NOT_RECRUITING | PHASE2 |
